← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIHEMORRHAGICS › VITAMIN K AND OTHER HEMOSTATICS › Fibrinogen
fibrinogen, human
B02BB01
Forms & Strengths
- Lyophilized powder for reconstitution: 1 g human fibrinogen per vial
Adult Dosing
- Congenital fibrinogen deficiency: 70 mg/kg IV once, then adjust based on target levels and clinical response
- Acquired hypofibrinogenemia/bleeding: 30 to 70 mg/kg IV initial dose, repeated as needed based on laboratory monitoring
Pediatric Dosing
- Congenital or acquired deficiency: 70 mg/kg IV, same as adult weight-based dosing; safety and efficacy established in pediatric patients
Indications
- Treatment of acute bleeding episodes in patients with congenital afibrinogenemia or hypofibrinogenemia
- Perioperative management of acute bleeding in acquired hypofibrinogenemia
Mechanism of Action
- Supplies exogenous human fibrinogen (Factor I), which is converted by thrombin into fibrin strands
- Fibrin strands are cross-linked by Factor XIIIa to form a stable mechanical blood clot, restoring hemostasis
Contraindications
- Known hypersensitivity to human fibrinogen or any product excipients
- History of severe anaphylactic or systemic reactions to blood products
Adverse Reactions
- Thromboembolic events (including myocardial infarction, pulmonary embolism, stroke)
- Allergic or anaphylactic reactions (urticaria, rash, hypotension, bronchospasm)
- Fever, chills, headache, nausea, and vomiting
- Risk of transmission of infectious agents (viral pathogens, vCJD) due to human plasma origin
Drug Interactions
- Antifibrinolytic agents (e.g., tranexamic acid, aminocaproic acid): may increase thrombotic risk when co-administered with procoagulants
- Anticoagulants (e.g., heparin, direct oral anticoagulants): antagonize the therapeutic hemostatic effect of fibrinogen concentrate
Curated Content: Needs Vetting Before Put to Clinical Use